Pioglitazone Hydrochloride in Treating Patients With Stage IA-IIIA Non-small Cell Lung Cancer

Summary

This pilot phase II trial studies how well pioglitazone works in treating patients with stage IA-IIIA non-small cell lung cancer. Pioglitazone hydrochloride may slow the growth of tumor cells and may be an effective treatment for non-small cell lung cancer.

Timeline

Start

2011-04

Primary completion

2012-12

Completion

2013-02

Outcome

Missed primary endpoint

registry analysis (superiority or other test); Treatment (Pioglitazone Hydrochloride); p = 0.06; Wilcoxon Signed Rank NCT01342770 ↗

Drugs

Indications